Gruber, Michaela
Bozic, Ivana
Leshchiner, Ignaty
Livitz, Dimitri
Stevenson, Kristen
Rassenti, Laura
Rosebrock, Daniel
Taylor-Weiner, Amaro
Olive, Oriol
Goyetche, Reaha
Fernandes, Stacey M.
Sun, Jing
Stewart, Chip
Wong, Alicia
Cibulskis, Carrie
Zhang, Wandi
Reiter, Johannes G.
Gerold, Jeffrey M.
Gribben, John G.
Rai, Kanti R.
Keating, Michael J.
Brown, Jennifer R.
Neuberg, Donna
Kipps, Thomas J.
Nowak, Martin A.
Getz, Gad
Wu, Catherine J.
Article History
Received: 26 August 2017
Accepted: 1 May 2019
First Online: 29 May 2019
Competing interests
: C.J.W. is founder of Neon Therapeutics and a member of its scientific advisory board. G.G. receives research funds from IBM and Pharmacyclics. G.G. is an inventor of several bioinformatics-related patents, including patents related to MuTect and ABSOLUTE. C.J.W., D.N. and T.J.K. receive research funding from Pharmacyclics. J.S. is a current employee of Moderna Therapeutics. J.G.G. receives grant funding from Janssen, Acerta, Celgene; and received honoraria from Abbvie, AZ, Celgene, Kite, Janssen, Pharmacyclics, Roche and Novartis. K.R.R. is on Medical Advisory Boards of Pharmacyclics, Roche/Genentech and Cellectis. J.R.B. is a consultant for Abbvie, Acerta, Beigene, Genentech/Roche, Gilead, Juno/Celgene, Kite, Loxo, Novartis, Pfizer, Pharmacyclics, Sunesis, TG Therapeutics and Verastem; received honoraria from Janssen and Teva; received research funding from Gilead, Loxo, Sun and Verastem; and served on data safety monitoring committees for Morphosys and Invectys. The other authors declare no potential conflicts of interest.